Genomics England and Lifebit will develop a trusted research environment to support cancer and rare disease studies. The partnership is described as creating secure, controlled digital workspaces that enable sensitive data sharing and computational analysis without moving data outside approved boundaries. The organizations plan over the next year to design, build, and test the environment and make it available to researchers sometime next year. The report notes Lifebit’s prior work on secure storage and management for a lung cancer study and on secure platforms for personalized medicine research. The initiative targets a practical bottleneck for rare disease analytics—scaling high-value computational work while maintaining data governance and access controls.